EU industry: new PV fee plan better, but still much room for improvement
This article was originally published in Scrip
Groups representing the innovator and generic pharmaceutical industries in Europe have welcomed the changes made by the European Commission to its original plans for a pharmacovigilance fee system, but say that there are still major problems with the proposal.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.